Zolmitriptan Spray
Product Images NDC 45802-711

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Zolmitriptan (NDC 45802-711). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Padagis Israel Pharmaceuticals Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

A line graph showing the estimated probability of response (%) over hours from initial dose for zolmitriptan nasal spray. It compares three treatments: 2.5 mg nasal spray, 5.0 mg nasal spray, and placebo. The graph illustrates increasing response probabilities over time, with the 5.0 mg dose showing the highest response, followed by 2.5 mg, and then placebo.*

FDA Label Image

Figure 2 (Image 02)

A line graph showing the estimated probability of taking escape medication (%) over 24 hours after the initial dose. The graph compares three treatments: 2.5 mg zolmitriptan nasal spray, 5.0 mg zolmitriptan nasal spray, and placebo. The x-axis represents hours from initial dose (0 to 24), and the y-axis represents the estimated probability (%) from 0 to 100.*

FDA Label Image

Figure 3 (Image 03)

A line graph showing the estimated probability of rescue medication use over 24 hours post-dose for zolmitriptan 5 mg and placebo groups. The x-axis represents time in hours post-dose, and the y-axis shows the percentage probability. Two curves compare zolmitriptan 5 mg (N=231) and placebo (N=253), with placebo showing a higher probability throughout.*

FDA Label Image

Figure-a (Image 04)

An instructional illustration showing a person opening a foil pouch containing zolmitriptan nasal spray USP 5 mg. The hands demonstrate peeling back the top of the pouch to access the spray device inside.*

FDA Label Image

Figure B (Image 05)

Illustration showing a person administering zolmitriptan nasal spray by placing a finger at the nostril, demonstrating the correct technique for intranasal drug delivery.*

FDA Label Image

Figure-c (Image 06)

An instructional illustration labeled 'Figure C' showing a hand holding a device for zolmitriptan nasal spray. The image highlights and labels two key parts of the device: the nozzle and the plunger.*

FDA Label Image

Figure D (Image 07)

An instructional illustration showing a person using a nasal spray. The person is holding the spray device towards one nostril while pointing with the other hand to the opposite side of the nose, demonstrating proper administration technique.*

FDA Label Image

Carton-7t0 (Image 09)

Packaging label for Zolmitriptan Nasal Spray, USP 5 mg by Padagis Israel Pharmaceuticals Ltd. The label indicates the product is a nasal spray for intranasal use only, available in a pack containing 6 single-use nasal spray devices. The label includes storage instructions, warnings, and manufacturer information from Perrigo.*

FDA Label Image

Chemical-structure (Image 10)

Chemical structure of zolmitriptan, the active ingredient in the product. The diagram shows the molecular arrangement and bonding within the zolmitriptan molecule.*

FDA Label Image

Serialization-template (Image 12)

A text panel showing placeholders for product identification information, including serial number (S/N), lot number, and expiration date (Exp). The placeholders prompt insertion of the product's specific serial number, lot number, and expiration date.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.